kabutan

Kidswell Bio Corporation(4584) Summary

4584
TSE Growth
Kidswell Bio Corporation
253
JPY
-1
(-0.39%)
Jan 29, 1:37 pm JST
1.65
USD
Jan 28, 11:38 pm EST
Result
PTS
outside of trading hours
252.2
Jan 29, 1:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.88
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
253 JPY 1.65 USD
Previous Close Jan 28
254 JPY 1.66 USD
High Jan 29, 9:00 am
256 JPY 1.67 USD
Low Jan 29, 9:42 am
243 JPY 1.58 USD
Volume
1,289,300
Trading Value
0.32B JPY 2.13M USD
VWAP
248.37 JPY 1.62 USD
Minimum Trading Value
25,300 JPY 165 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
707
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
1,176
1-Year High Jan 22, 2026
11,856
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 600 5,321,900 8869.83
Jan 16, 2026 0 4,265,200
Jan 9, 2026 0 4,314,800
Dec 26, 2025 0 4,221,300
Dec 19, 2025 0 4,418,200
Company Profile
Kidswell Bio Corporation is a drug discovery venture originating from Hokkaido University. The company focuses on biopharmaceuticals, biosimilars, antibody drugs, and pediatric medicines.
Sector
Pharmaceuticals
Kidswell Bio Corporation, a drug discovery venture born out of Hokkaido University, initially operated in three business areas: biopharmaceuticals, biosimilars, and cell therapy (regenerative medicine). However, to maximize corporate value and achieve rapid stock price recovery and growth, the company has shifted its strategy to concentrate management resources on the biosimilar business, which provides a stable revenue base, and the cell therapy business, which serves as a growth foundation. In the biosimilar business, the company has been involved in the development of four products, establishing a stable revenue base through sales of launched products. In the cell therapy business, Kidswell Bio is advancing the development of regenerative medicine products utilizing stem cells from deciduous tooth dental pulp (SHED). The company is responsible for manufacturing process development and active pharmaceutical ingredient supply in the biosimilar business, and covers from basic research to manufacturing in the cell therapy business. Both business segments emphasize partnerships with pharmaceutical companies, and the company is actively working to expand its operations.